An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
| Autor: | Y.S. Babu, Amanda Mathis, Justin G. Julander, Brian B. Gowen, Dennis M. Walling, Ray Taylor, James F. Demarest |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
RNA viruses
Adenosine Pyrrolidines Nucleoside analog viruses Drug Evaluation Preclinical BCX4430 Antiviral Agents Article Marburg virus Marburg virus disease Virology medicine Animals Rift Valley fever Antiviral Pharmacology biology Clinical Trials Phase I as Topic business.industry SARS-CoV-2 Adenine Yellow fever Nucleosides medicine.disease Marburgvirus biology.organism_classification Cell culture Viral disease business |
| Zdroj: | Antiviral Research |
| ISSN: | 1872-9096 |
| Popis: | Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect